Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.XOMA, a company that discovers and develops therapeutic antibodies, has received $750,000 milestone payment from AVEO Pharmaceuticals, under a collaboration signed between both the companies,
Subscribe to our email newsletter
XOMA and AVEO said that the milestone payment resulted from AVEO’s recent commencement of AV-299 Phase 2 clinical trial to evaluate its antibody for the treatment of non-small cell lung cancer.
AVEO said that AV-299 is a humanised antibody to hepatocyte growth factor (HGF).
XOMA and AVEO entered into a $6m supply agreement on September 28, 2006, under which XOMA was responsible to manufacture and supply AV-299.
Under the supply agreement, XOMA was expected to create AV-299 production cell lines, and conduct process and assay development, as well as cGMP manufacturing activities in support of AVEO’s IND filing and early clinical trials.
Earlier, on April 27, 2006, XOMA and AVEO signed another agreement under which XOMA would use its HE technology to humanise AV-299. XOMA created four Human Engineered versions of the original AV-299, all of which met design goals and were delivered ahead of schedule.